| Bioactivity | sRANKL-IN-1 (compound S3) is a sRANKL (soluble RANKL) inhibitor. sRANKL-IN-1 shows a potent osteoclast inhibition effect with an IC50 value of 0.096 μM and a KD value of 34.80 μM. sRANKL-IN-1 can be used for the research of osteoporosis[1]. |
| Target | IC50: 0.096 μM (osteoclast) |
| Invitro | sRANKL-IN-1 (0-50 μM) shows potent inhibition to osteoclast[1]. Cell Viability Assay[1] Cell Line: |
| Name | sRANKL-IN-1 |
| CAS | 331968-10-6 |
| Formula | C18H18N4O6S |
| Molar Mass | 418.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Huang D, et al. Identification of a binding site on soluble RANKL that can be targeted to inhibit soluble RANK-RANKL interactions and treat osteoporosis. Nat Commun. 2022 Sep 12;13(1):5338. |
sRANKL-IN-1
CAS: 331968-10-6 F: C18H18N4O6S W: 418.42
sRANKL-IN-1 (compound S3) is a sRANKL (soluble RANKL) inhibitor. sRANKL-IN-1 shows a potent osteoclast inhibition effect
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.